QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=4DA2ED7BBCCA5CAD0216612FD8B5B135;jsessionid=402CD09D12027F9CEE86DE7EF9FFC046;jsessionid=C1BBDD0CBC8923CE4F9AFF45C3B8347C;jsessionid=A651D96718FA2717605410C365B16C06;jsessionid=80724429343A228AEB62730113E25FAF;jsessionid=87D50AD7994C004A6A11E3502B48522F;jsessionid=CCEDD60A81C88054056332882336FE42;jsessionid=87F9200C92D03D551D839C14F36A3A3C (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=4DA2ED7BBCCA5CAD0216612FD8B5B135;jsessionid=402CD09D12027F9CEE86DE7EF9FFC046;jsessionid=C1BBDD0CBC8923CE4F9AFF45C3B8347C;jsessionid=A651D96718FA2717605410C365B16C06;jsessionid=80724429343A228AEB62730113E25FAF;jsessionid=87D50AD7994C004A6A11E3502B48522F;jsessionid=CCEDD60A81C88054056332882336FE42;jsessionid=87F9200C92D03D551D839C14F36A3A3C